Development of Pneumocystis pneumonia (PCP) is a common problem among immunosuppressed individuals. There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccines have made it to clinical trials. Significant hurdles to vaccine development include host range specificity, making it difficult to translate from animal models to humans. Discovery of cross-reactive epitopes is critical to moving vaccine candidates from preclinical animal studies to clinical trials.
Digital Object Identifier (DOI)
This work was supported in part by grant AI118818 from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, U.S. Department of Health and Human Services.
Garvy, Beth A., "Overcoming Hurdles to Development of a Vaccine Against Pneumocystis jirovecii" (2017). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 97.